EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR 74 & 75-Year-Old Sweethearts Get Married In ICU In Wake Of... February 10, 2022 Singer Surprises 6-Year-Old Fan Who Beat Cancer With Trip To Disney January 10, 2022 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 NHS England Lung Cancer Screening Programme Demonstrates that it is Feasible and Scalable... April 3, 2026 Load more HOT NEWS Cancer in My Community: Providing Free Access to Cancer Care in... Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... How Genomic Testing Brought Me a Sense of Control During Metastatic...
